The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer

U. Meyer; C. Dierig; N. Katopodis; C.H.M.M. Bruijn, de

The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer

U. Meyer, C. Dierig, N. Katopodis, C.H.M.M. Bruijn, de

Chemical Engineering and Chemistry

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

1 Downloads (Pure)

Abstract

According to the most recent US cancer statistics, prostatic cancer almost equals lung cancer as the most frequent cause of death from cancer in men. The search for diagnostic methods as well as control examinations have therefore gained great importance. The present study reveals that--in addition to rectal touch, sonography and biopsy of the prostate--the determination of both PSA as organ-specific marker and lipid-associated sialic acid (LSA) as a general tumor marker, is well suited for follow-up and monitoring treatment. With regard to the follow-up, the combined determination of PSA and LSA in serum of patients with prostatic cancer achieves a higher sensitivity as compared to PSA alone (increase of 30-40%). LSA is a good indicator for the presence of metastases. Therefore, the determination of LSA should become an integral part of treatment monitoring and detection of metastatic disease in patients with prostatic cancer.

Original language	English
Pages (from-to)	1889-1894
Journal	Anticancer Research
Volume	13
Publication status	Published - 1993

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Fingerprint Dive into the research topics of 'The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer'. Together they form a unique fingerprint.

Cite this

@article{915ad837c0a64cc085cc117e33cd0515,

title = "The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer",

abstract = "According to the most recent US cancer statistics, prostatic cancer almost equals lung cancer as the most frequent cause of death from cancer in men. The search for diagnostic methods as well as control examinations have therefore gained great importance. The present study reveals that--in addition to rectal touch, sonography and biopsy of the prostate--the determination of both PSA as organ-specific marker and lipid-associated sialic acid (LSA) as a general tumor marker, is well suited for follow-up and monitoring treatment. With regard to the follow-up, the combined determination of PSA and LSA in serum of patients with prostatic cancer achieves a higher sensitivity as compared to PSA alone (increase of 30-40%). LSA is a good indicator for the presence of metastases. Therefore, the determination of LSA should become an integral part of treatment monitoring and detection of metastatic disease in patients with prostatic cancer.",

author = "U. Meyer and C. Dierig and N. Katopodis and {Bruijn, de}, C.H.M.M.",

year = "1993",

language = "English",

volume = "13",

pages = "1889--1894",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer

AU - Meyer, U.

AU - Dierig, C.

AU - Katopodis, N.

AU - Bruijn, de, C.H.M.M.

PY - 1993

Y1 - 1993

N2 - According to the most recent US cancer statistics, prostatic cancer almost equals lung cancer as the most frequent cause of death from cancer in men. The search for diagnostic methods as well as control examinations have therefore gained great importance. The present study reveals that--in addition to rectal touch, sonography and biopsy of the prostate--the determination of both PSA as organ-specific marker and lipid-associated sialic acid (LSA) as a general tumor marker, is well suited for follow-up and monitoring treatment. With regard to the follow-up, the combined determination of PSA and LSA in serum of patients with prostatic cancer achieves a higher sensitivity as compared to PSA alone (increase of 30-40%). LSA is a good indicator for the presence of metastases. Therefore, the determination of LSA should become an integral part of treatment monitoring and detection of metastatic disease in patients with prostatic cancer.

AB - According to the most recent US cancer statistics, prostatic cancer almost equals lung cancer as the most frequent cause of death from cancer in men. The search for diagnostic methods as well as control examinations have therefore gained great importance. The present study reveals that--in addition to rectal touch, sonography and biopsy of the prostate--the determination of both PSA as organ-specific marker and lipid-associated sialic acid (LSA) as a general tumor marker, is well suited for follow-up and monitoring treatment. With regard to the follow-up, the combined determination of PSA and LSA in serum of patients with prostatic cancer achieves a higher sensitivity as compared to PSA alone (increase of 30-40%). LSA is a good indicator for the presence of metastases. Therefore, the determination of LSA should become an integral part of treatment monitoring and detection of metastatic disease in patients with prostatic cancer.

M3 - Article

VL - 13

SP - 1889

EP - 1894

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

ER -